Table 2.
Treatment characteristics.
| Characteristics | n or Median (% or Range) |
|---|---|
| GTV | 50 (21–120) mL |
| PTV | 160 (75–331) mL |
| Prescribed dose | |
| 61.6 Gy (RBE)/28 fr. | 1 (7) |
| 66.0 Gy (RBE)/30 fr. | 4 (26) |
| 70.4 Gy (RBE)/32 fr. | 4 (26) |
| 72.6 Gy (RBE)/33 fr. | 1 (7) |
| others | 5 (33) |
| Total radiation dose | |
| BED10 | 84.4 (75.2–88.6) Gy (RBE) |
| BED3 | 119.1 (106.8–125.8) Gy (RBE) |
| EQD10/2 | 70.3 (62.6–73.8) Gy (RBE) |
| EQD3/2 | 71.5 (64.1–75.5) Gy (RBE) |
| Total dose of cisplatin on IAIC | 410 (200–580) mg |
| Arterial injection vessels | |
| LA + ECA | 6 (40) |
| LA | 1 (7) |
| ECA | 8 (53) |
| Nutrition | |
| PEG | 6 (40) |
| Oral intake | 5 (33) |
| Naso-gastric tube | 4 (26) |
Abbreviations: GTV, gross tumor volume; PTV, planning target volume; RBE, relative biological effectiveness; BED, biological effective dose; EQD10/2, equivalent dose as 2-Gy fractions for α/β = 10; EQD3/2, equivalent dose as 2-Gy fractions for α/β = 3; IAIC, intra-arterial infusion chemotherapy; LA, lingual artery; ECA, external carotid artery; PEG, percutaneous endoscopic gastrostomy.